Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

in Endocrine-Related Cancer
Authors:
R I Nicholson Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by R I Nicholson in
Current site
Google Scholar
PubMed
Close
,
I R Hutcheson Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by I R Hutcheson in
Current site
Google Scholar
PubMed
Close
,
M E Harper Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by M E Harper in
Current site
Google Scholar
PubMed
Close
,
J M Knowlden Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by J M Knowlden in
Current site
Google Scholar
PubMed
Close
,
D Barrow Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by D Barrow in
Current site
Google Scholar
PubMed
Close
,
R A McClelland Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by R A McClelland in
Current site
Google Scholar
PubMed
Close
,
H E Jones Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by H E Jones in
Current site
Google Scholar
PubMed
Close
,
A E Wakeling Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by A E Wakeling in
Current site
Google Scholar
PubMed
Close
, and
J M Gee Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK. nicholsonri@cardiff.ac.uk

Search for other papers by J M Gee in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

There is an increasing body of evidence demonstrating that growth factor networks are highly interactive with oestrogen receptor (ER) signalling in the control of breast cancer growth. As such, tumour responses to anti- hormones are likely to be a composite of the ER and growth factor inhibitory activity of these agents. The current article examines the modulation of growth factor networks during endocrine response, and presents in vitro and clinical evidence that epidermal growth factor receptor signalling, maintained in either an ER-dependent or -independent manner, is critical to anti- hormonal-resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor, ZD 1839 (Iressa; AstraZeneca) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.